⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135839 | 0.86 | — | — | |
| SCHEMBL6244855 | 0.86 | — | — | |
| Dodecane SCHEMBL2499543 | 0.85 | ALDH1A1 (0.50) | — | |
| SCHEMBL27501951 | 0.82 | — | — | |
| SCHEMBL27802096 | 0.82 | — | — | |
| SCHEMBL27600271 | 0.82 | — | — | |
| Methane SCHEMBL1676856 | 0.82 | — | — | |
| SCHEMBL28129102 | 0.82 | — | — | |
| Ethane SCHEMBL177534 | 0.82 | — | — | |
| SCHEMBL27554077 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-23 | — | — | US | disclosed |
| EP-2046802-A2 | NOVEL 2-SUBSTITUTED METHYL PENAM DERIVATIVES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008010048-A2 | NOVEL 2-SUBSTITUTED METHYL PENAM DERIVATIVES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-01-24 | — | — | WO | disclosed |
| EP-1877389-A1 | SYNTHESIS OF CYCLEN DERIVATIVES | GE Healthcare AS (NO) | 2008-01-16 | — | — | EP | disclosed |
| EP-1725522-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006112723-A1 | SYNTHESIS OF CYCLEN DERIVATIVES | GE HEALTHCARE AS (NO) | 2006-10-26 | — | — | WO | disclosed |
| WO-2005085185-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| US-6506876-B1 | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. | 2003-01-14 | — | — | US | disclosed |
| EP-0804427-B1 | LTA4 HYDROLASE INHIBITORS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | disclosed |
| US-5723492-A | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5719306-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |